Pfizer Stock Price, News & Analysis

Pfizer (NYSE:PFE) will showcase its oncology portfolio at the ESMO Congress 2025 in Berlin, featuring over 45 abstracts, including 5 late-breaking presentations and recognition in the Presidential Symposium.

Key highlights include the Phase 3 EV-303 trial results for PADCEV® plus KEYTRUDA® in muscle-invasive bladder cancer, final survival data from the Phase 3 EMBARK trial evaluating XTANDI® in prostate cancer, and updated survival data from the Phase 2 PHAROS study of BRAFTOVI® plus MEKTOVI® in BRAF V600E-mutant metastatic NSCLC.

The presentations span multiple cancer types, including genitourinary, thoracic, breast, and gastrointestinal cancers, demonstrating Pfizer's commitment to advancing cancer treatment standards through innovative medicines and earlier interventions.

Pfizer (NYSE: PFE) has announced a conference call with investment analysts scheduled for November 4, 2025, at 10:00 a.m. EST. The call will discuss Pfizer's Third Quarter 2025 Performance Report, which will be released that morning.

Investors and the public can access the webcast through www.pfizer.com/investors. Alternative access is available via phone at 800-456-4352 (US/Canada) or 785-424-1086 (International) using passcode "90164". The webcast replay and transcript will be available on Pfizer's website within 24 hours after the call and will remain accessible for at least 90 days.

Pfizer (NYSE:PFE) has announced a definitive agreement to acquire Metsera (NASDAQ:MTSR) in a deal valued at $47.50 per share in cash, representing an enterprise value of $4.9 billion. The deal includes a CVR worth up to $22.50 per share tied to clinical and regulatory milestones.

The acquisition brings Pfizer four clinical-stage incretin and amylin programs targeting obesity and cardiometabolic diseases. Key assets include MET-097i, a weekly and monthly injectable GLP-1 receptor agonist in Phase 2, and MET-233i, a monthly amylin analog in Phase 1, along with two oral GLP-1 RA candidates.

The transaction is expected to close in Q4 2025, subject to regulatory approvals and Metsera shareholder approval. This strategic move positions Pfizer in the growing obesity therapeutic area, which is associated with over 200 health conditions.

Pfizer (NYSE:PFE) and BioNTech have announced positive topline results from their Phase 3 clinical trial of the LP.8.1-adapted COVID-19 vaccine 2025-2026 Formula. The study involved 100 participants, including adults aged 65+ and those 18-64 with risk conditions for severe COVID-19.

The trial demonstrated that 14 days post-vaccination, participants showed at least a 4-fold increase in LP.8.1-neutralizing antibody titers compared to pre-vaccination levels. The safety profile remained consistent with previous studies, with no new safety concerns identified.

These findings support the recent FDA approval of the LP.8.1-adapted COVID-19 vaccine and reinforce its potential effectiveness against multiple circulating SARS-CoV-2 sublineages.

Pfizer (NYSE:PFE) and Astellas Pharma announced positive Phase 3 trial results for PADCEV plus KEYTRUDA in treating muscle-invasive bladder cancer (MIBC). The EV-303 study demonstrated that the combination therapy, when used before and after surgery, achieved statistically significant improvements in both event-free survival and overall survival compared to surgery alone in cisplatin-ineligible patients.

The groundbreaking results represent the first significant treatment advance in decades for MIBC patients who cannot receive cisplatin treatment. The combination therapy also met its secondary endpoint of pathologic complete response rate. The safety profile remained consistent with known profiles of each treatment.

Pfizer (NYSE:PFE) reported strong Q2 2025 financial results, with revenues reaching $14.7 billion, marking a 10% year-over-year operational growth. The company achieved Adjusted diluted EPS of $0.78, a 30% increase from the previous year. Pfizer reaffirmed its 2025 revenue guidance of $61.0 to $64.0 billion and raised its Adjusted diluted EPS guidance to $2.90-$3.10.

Key growth drivers included the Vyndaqel family (+21%), Comirnaty (+95%), and Paxlovid (+71%). The company remains on track to deliver approximately $7.2 billion in net cost savings by 2027. The guidance includes absorption of a $1.35 billion one-time charge related to the 3SBio transaction, impacting EPS by approximately $0.20.

Pfizer (NYSE:PFE) has completed a global licensing agreement with 3SBio for SSGJ-707, a bispecific antibody targeting PD-1 and VEGF for cancer treatment. The deal excludes China and involves a $1.25 billion payment plus a $100 million equity investment in 3SBio.

SSGJ-707 has shown positive Phase 2 results in non-small cell lung cancer (NSCLC) and is being tested for other cancers. Pfizer plans to manufacture the drug in North Carolina and Kansas facilities, with upcoming Phase 3 global trials focusing on NSCLC and other solid tumors. The agreement includes an option for China rights for up to $150 million in additional payments.

Bristol Myers Squibb (NYSE:BMY) and Pfizer have announced a significant direct-to-patient program for their anticoagulant medication Eliquis® (apixaban). Starting September 8, 2025, eligible U.S. patients can purchase Eliquis directly through the Eliquis 360 Support program at a 40% discount from the current list price.

The program will provide direct shipping across all 50 states and Puerto Rico, offering simplified access and cost transparency. With over 15 million Americans prescribed Eliquis since launch, the medication has generated an estimated $3 billion in healthcare cost savings per 100,000 patients treated through reduced hospitalizations and rehabilitation needs.

ViiV Healthcare, majority owned by GSK with Pfizer (NYSE:PFE) as shareholder, reported significant findings for their HIV treatments. The phase IIIb VOLITION study showed that 89% of treatment-naïve HIV patients chose to switch to long-acting injectable Vocabria + Rekambys after achieving viral suppression with daily Dovato.

Multiple real-world studies demonstrated strong effectiveness: The BEYOND study showed 97% maintained virologic suppression at Month 24, the CARLOS study reported 77.5% virologic suppression with 94.2% on-time injections, and COMBINE-2 revealed 99% virologic suppression across seven European countries.

Implementation studies for Apretude (CAB LA for PrEP) showed 95% satisfaction among participants who switched from oral PrEP, with high acceptability ratings of 4.6/5 at Month 12.